サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574947

抗ウイルス剤併用療法市場：薬剤タイプ別、薬剤併用療法別、投与経路別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

Antiviral Combination Therapy Market, By Drug Type, By Drug Combination, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗ウイルス剤併用療法市場：薬剤タイプ別、薬剤併用療法別、投与経路別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

抗ウイルス剤併用療法の市場規模は2023年に490億1,921万米ドルとなり、2024年から2032年にかけてCAGR 6.40%で拡大

抗ウイルス剤併用療法市場- 市場力学

耐性ウイルスの増加により、革新的な抗ウイルス剤併用療法が必要とされています。

ウイルス耐性の増加は、抗ウイルス剤併用療法市場の主要促進要因です。ウイルスは時間の経過とともに変化するため、現在の治療法に対して耐性を獲得し、治療効果が低下する可能性があります。このような状況から、耐性ウイルスによりよく効く新しい革新的な治療法が必要とされています。異なる抗ウイルス薬を組み合わせて使用することで、ヘルスケアプロバイダーは複数の方法でウイルスを攻撃することができ、成功の可能性が高まります。患者は頑固な感染症に対する効果的な治療法を必要としており、このような併用療法への需要が高まっています。その結果、抗ウイルス剤併用療法の市場は、この重要なニーズを満たすために成長しています。

抗ウイルス剤併用療法市場-主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約6.40%のCAGRで毎年成長すると推定されます。

薬剤タイプ別では、ブランド薬が2023年に最大の市場シェアを示すと予測されています。

薬剤併用療法別では、2023年には逆転写酵素阻害薬が主要な薬剤タイプでした。

投与経路別では、経口剤が2023年の主要薬物タイプでした。

適応症別では、ヒト免疫不全ウイルス（HIV）治療薬が2023年のトップ

地域別では、北米が2023年の売上高をリード

抗ウイルス剤併用療法市場-セグメンテーション分析：

抗ウイルス剤併用療法の世界市場は、薬剤タイプ、薬剤併用療法、投与経路、適応症、地域に基づいて区分されます。

薬剤の組み合わせにより、市場は4つのカテゴリーに分けられます。DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、プロテアーゼ阻害剤、ノイラミニダーゼ阻害剤、その他。特に重要なのは逆転写酵素阻害剤です。これらの薬剤は主にHIVの治療に用いられ、ウイルスの複製に重要な逆転写酵素を標的とします。併用療法におけるその有効性は、HIV管理を一変させ、ウイルス量を減少させ、患者の転帰を改善しました。新たな逆転写酵素阻害剤の開発が進行中であることも、薬剤耐性への対応や治療選択肢の拡大における逆転写酵素阻害剤の重要性を浮き彫りにしています。このセグメントは治療効果と患者のアドヒアランスの両面で重要な役割を担っており、抗ウイルス剤市場における優位性を裏付けています。

同市場は適応症別に2つのカテゴリーに分類される：ヒト免疫不全ウイルス（HIV）、肝炎、その他のウイルス感染症です。ヒト免疫不全ウイルス（HIV）分野が最も顕著です。HIV治療は年々著しく進歩しており、併用療法によりウイルス量を効果的に減少させ、患者のQOLを向上させています。HIVの撲滅に世界的に注力し、革新的な治療法を開発し続けていることが、このセグメントの優位性に寄与しています。さらに、HIVの有病率の高さと治療に対する認識やアクセスの向上が、抗ウイルス剤市場におけるこの分野の重要性を確固たるものにしています。

抗ウイルス剤併用療法市場-地理的洞察

北米の抗ウイルス剤併用療法市場は急成長しています。この成長の背景には、ウイルス感染症の増加と、より効果的な治療の必要性があります。多くの企業が、患者の予後を改善するための新薬併用療法の開発に注力しています。

耐性ウイルス株の増加も、こうした治療法の需要を押し上げています。病院や診療所がこれらの治療法をより広く採用することで、売上の増加につながります。政府の支援や研究資金も企業の技術革新を後押ししています。

抗ウイルス剤併用療法市場-競合情勢：

抗ウイルス剤併用療法市場では、複数の主要企業が市場シェアを争っています。ギリアド・サイエンシズとアッヴィは、有効性を高める革新的な併用療法でHIV治療をリードしています。Merck &Co.とGlaxoSmithKlineは、インフルエンザやその他のウイルス感染症に対する抗ウイルス療法に注力しています。ブリストル・マイヤーズスクイブとジョンソン・エンド・ジョンソンは、様々なウイルス性疾患の治療法を開発しています。アストラゼネカとロシュは独自の治療法で貢献し、ファイザーとノバルティスは肝炎やその他の疾患に対する新しい組み合わせを模索しています。これらの企業は常に革新的で、患者の転帰を改善し、抗ウイルス領域での製品提供を拡大することを目指しています。

目次

第1章 抗ウイルス剤併用療法市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 抗ウイルス剤併用療法の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 抗ウイルス剤併用療法産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 抗ウイルス剤併用療法市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 抗ウイルス剤併用療法市場情勢

  • 抗ウイルス剤併用療法市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 抗ウイルス剤併用療法市場- 薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • ブランド
    • ジェネリック

第8章 抗ウイルス剤併用療法市場- 薬剤併用療法別

  • 概要
    • 薬剤併用療法別セグメントシェア分析
    • DNAポリメラーゼ阻害剤
    • 逆転写酵素阻害剤
    • プロテアーゼ阻害剤
    • ノイラミニダーゼ阻害剤
    • その他

第9章 抗ウイルス剤併用療法市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 静脈内

第10章 抗ウイルス剤併用療法市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • ヒト免疫不全ウイルス
    • 肝炎
    • その他

第11章 抗ウイルス剤併用療法市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 抗ウイルス剤併用療法業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Gilead Sciences
    • AbbVie
    • Merck &Co.
    • GlaxoSmithKline（GSK）
    • Bristol-Myers Squibb
    • Johnson &Johnson
    • AstraZeneca
    • Roche
    • Pfizer
    • Novartis
    • Sanofi
    • Vertex Pharmaceuticals
    • Hoffmann-La Roche
    • Regeneron Pharmaceuticals
    • Eli Lilly and Company

第13章 アナリストの全方位展望

目次
Product Code: ANV3950

REPORT HIGHLIGHT

Antiviral Combination Therapy Market size was valued at USD 49,019.21 million in 2023, expanding at a CAGR of 6.40% from 2024 to 2032.

Antiviral combination therapy is a treatment approach that uses two or more antiviral drugs together to fight viral infections. This method helps improve effectiveness by targeting different parts of the virus or its life cycle, making it harder for the virus to survive and multiply. It is often used to treat diseases like HIV and hepatitis. By combining multiple drugs, this method lowers the chances of the virus developing resistance to treatment. This strategy can result in improved health for patients and help limit the spread of infections.

Antiviral Combination Therapy Market- Market Dynamics

Rising viral resistance necessitates innovative antiviral combination therapies for effectiveness.

Rising viral resistance is a key driver for the antiviral combination therapy market. As viruses change over time, they can become resistant to current treatments, making them less effective. This situation creates the need for new and innovative therapies that can work better against these resistant viruses. By using a combination of different antiviral drugs, healthcare providers can attack the virus in multiple ways, increasing the chances of success. Patients require effective treatments for stubborn infections, leading to a higher demand for these combination therapies. As a result, the market for antiviral combination therapies is growing to meet this important need.

Antiviral Combination Therapy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.40% over the forecast period (2024-2032)

Based on Drug Type segmentation, Branded was predicted to show maximum market share in the year 2023

Based on Drug Combination segmentation, Reverse Transcriptase Inhibitors was the leading Drug Type in 2023

Based on Route of Administration segmentation, Oral was the leading Drug Type in 2023

Based on Indication segmentation, Human Immunodeficiency Virus (HIV), was the leading Drug Type in 2023

based on Region, North America was the leading revenue generator in 2023

Antiviral Combination Therapy Market- Segmentation Analysis:

The Global Antiviral Combination Therapy Market is segmented based on Drug Type, Drug Combination, Route of Administration, Indication, and Region.

The market is divided into four categories based on Drug Combination. DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The Reverse Transcriptase Inhibitors are particularly significant. These drugs, primarily used in the treatment of HIV, target the reverse transcriptase enzyme crucial for viral replication. Their effectiveness in combination therapies has transformed HIV management, reduced viral load, and improved patient outcomes. The ongoing development of new reverse transcriptase inhibitors also highlights their prominence in addressing drug resistance and enhancing therapeutic options. This segment's critical role in both treatment efficacy and patient adherence underscores its dominance in the antiviral market.

The market is divided into two categories based on Indication: Human Immunodeficiency Virus (HIV), Hepatitis, and other viral infections. The Human Immunodeficiency Virus (HIV) segment is the most prominent. HIV treatment has advanced significantly over the years, with combination therapies effectively reducing viral loads and improving the quality of life for patients. The global focus on eradicating HIV and the ongoing development of innovative therapies contribute to this segment's dominance. Furthermore, the high prevalence of HIV, coupled with rising awareness and access to treatment, solidifies its significance in the antiviral market landscape.

Antiviral Combination Therapy Market- Geographical Insights

The antiviral combination therapy market in North America is growing rapidly. This growth is driven by an increasing number of viral infections and the need for more effective treatments. Many companies are focusing on developing new drug combinations to improve patient outcomes.

The rise of resistant viral strains also boosts demand for these therapies. Hospitals and clinics adopting these treatments more widely, leading to higher sales. Government support and research funding are helping companies innovate.

Antiviral Combination Therapy Market- Competitive Landscape:

The antiviral combination therapy market features several key players competing for market share. Gilead Sciences and AbbVie lead in HIV treatments, with innovative combinations that enhance efficacy. Merck & Co. and GlaxoSmithKline focus on antiviral therapies for influenza and other viral infections. Bristol-Myers Squibb and Johnson & Johnson are significant, developing treatments for various viral diseases. AstraZeneca and Roche contribute with their unique therapies, while Pfizer and Novartis explore new combinations for hepatitis and other conditions. these companies are constantly innovating, aiming to improve patient outcomes and expand their product offerings in the antiviral space.

Recent Developments:

In March 2024, Gilead Sciences completed its acquisition of CymaBay Therapeutics, enhancing its portfolio in the field of liver disease treatments. This strategic move aims to bolster Gilead's pipeline with CymaBay's promising therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • GlaxoSmithKline (GSK)
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • AstraZeneca
  • Roche
  • Pfizer
  • Novartis
  • Sanofi
  • Vertex Pharmaceuticals
  • Hoffmann-La Roche
  • Regeneron Pharmaceuticals
  • Eli Lilly and Company

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generic

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY DRUG COMBINATION- MARKET ANALYSIS, 2019 - 2032

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Human Immunodeficiency Virus
  • Hepatitis
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antiviral Combination Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiviral Combination Therapy Market Snippet by Drug Type
    • 2.1.2. Antiviral Combination Therapy Market Snippet by Drug Combination
    • 2.1.3. Antiviral Combination Therapy Market Snippet by Route of Administration
    • 2.1.4. Antiviral Combination Therapy Market Snippet by Indication
    • 2.1.5. Antiviral Combination Therapy Market Snippet by Country
    • 2.1.6. Antiviral Combination Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiviral Combination Therapy Key Market Trends

  • 3.1. Antiviral Combination Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiviral Combination Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiviral Combination Therapy Market Opportunities
  • 3.4. Antiviral Combination Therapy Market Future Trends

4. Antiviral Combination Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiviral Combination Therapy Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiviral Combination Therapy Market Landscape

  • 6.1. Antiviral Combination Therapy Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiviral Combination Therapy Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Branded
    • 7.1.3. Generic

8. Antiviral Combination Therapy Market - By Drug Combination

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Combination, 2023 & 2032 (%)
    • 8.1.2. DNA Polymerase Inhibitors
    • 8.1.3. Reverse Transcriptase Inhibitors
    • 8.1.4. Protease Inhibitors
    • 8.1.5. Neuraminidase Inhibitors
    • 8.1.6. Others

9. Antiviral Combination Therapy Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Antiviral Combination Therapy Market - By Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Drug Combination, 2023 & 2032 (%)
    • 10.1.2. Human Immunodeficiency Virus
    • 10.1.3. Hepatitis
    • 10.1.4. Others

11. Antiviral Combination Therapy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antiviral Combination Therapy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antiviral Combination Therapy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antiviral Combination Therapy Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antiviral Combination Therapy Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antiviral Combination Therapy Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Antiviral Combination Therapy Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. AbbVie
    • 12.2.3. Merck & Co.
    • 12.2.4. GlaxoSmithKline (GSK)
    • 12.2.5. Bristol-Myers Squibb
    • 12.2.6. Johnson & Johnson
    • 12.2.7. AstraZeneca
    • 12.2.8. Roche
    • 12.2.9. Pfizer
    • 12.2.10. Novartis
    • 12.2.11. Sanofi
    • 12.2.12. Vertex Pharmaceuticals
    • 12.2.13. Hoffmann-La Roche
    • 12.2.14. Regeneron Pharmaceuticals
    • 12.2.15. Eli Lilly and Company

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us